



Medicines

UCLPartners Opioids Programme

Jessica Catone – Implementation Manager

January 2024

 @UCLPartners

www.uclpartners.com

Delivered by:
UCLPartners
Patient Safety Collaborative

**Health
Innovation
Network**

Led by:
**NHS England
NHS Improvement**

MS Teams Housekeeping



Cameras



Mute



Questions



Chatbox



Keeping to time



The session will
be recorded

Agenda

Time	Item	Lead
12:00	Welcome and introductions	Jess Catone
12:05	Overview of MedSIP	Jess Catone
12:10	Background of discharge letter audits	Amandeep Setra
12:20	QI methodology	Jess Catone
12:45	Discussion: applying QI methodology to discharge letter improvements	Jess Catone
13:00	Example from Newham MSK collaboration community pain clinic	Irun Nandra
13:20	Questions and next steps	Jess Catone
13.30	Close	Jess Catone

National Medicines Safety Improvement Programme (MedSIP)

- Aim: reduce prescribing of high dose opioids (> 120mg oral morphine) in non-cancer pain by 50% by March 2024
- Chronic non-cancer pain management requires personalised care and shared decision-making, using a mixture of biopsychosocial support so patients can live well with pain.
- [NHSE estimate](#) that **1 life can be saved for every 62 patients** with chronic pain who could manage their pain without opioids
 - ~ 6000 people a year will be hospitalised with adverse events whilst taking opioids for extended periods

National Medicines Safety Improvement Programme (MedSIP)

- NCL / NEL joint core working group
 - Meetings every 6-8 weeks
- Set up UCLPartners Opioids Network
 - Every 3 months
 - Completed 4 Network meetings
- Primary care clinicians survey
 - 169 responses over 2 weeks
- Group Education Sessions

Discharge Letter Audit Background

- Aim is to improve communication between secondary care and primary care when patients are put on a new opioid
- ‘Turning off the tap’ on new instances of patients being on long-term opioids
- Questions:
 - Indication for opioid
 - Which medication
 - PRN / regular / both
 - Opioid included in discharge letter under meds
 - Duration for opioid / review/stop date
 - Future plan for opioid (e.g., when/how to reduce)

National Patient Safety Improvement Programmes
Medicines

UCLPartners

Opioid Prescribing Audit

The aim of this opioid prescribing audit is to review the information included on discharge letters for **newly initiated weak and strong opioids**. This includes codeine, dihydrocodeine, tramadol, co-codamol, co-dydramol, morphine, fentanyl, buprenorphine, oxycodone, pethidine, tapentadol and hydromorphone. Please complete one table for each patient on the ward(s) being audited who were newly started on a weak or strong opioid according to their last discharge letter. This audit should be completed retrospectively over a period of 2-4 weeks. Standard: 100% of discharge letters with newly initiated opioids should include indication and duration of medication or information on when to review/reduce dose.

Patients age	
Was the patient taking opioid medication prior to this hospital admission (weak or strong)?	Yes <input type="checkbox"/> No <input type="checkbox"/> <i>If yes, this person is not eligible for inclusion in this audit.</i>
What is the indication for starting the opioid medication? i.e. location of pain/type of surgery etc.	
Which opioid medication(s) have been initiated?	
Is the opioid PRN, regular or both?	PRN <input type="checkbox"/> Regular <input type="checkbox"/> Both <input type="checkbox"/>
Are the opioid(s) included on the discharge letter under medications?	Yes <input type="checkbox"/> No <input type="checkbox"/>
Has the prescriber added a duration for the opioid(s) or when it/they should be reviewed/stopped?	Yes <input type="checkbox"/> No <input type="checkbox"/>
Has the prescriber added any information regarding the future plan for the opioid? i.e. when or how to reduce the dose?	Yes <input type="checkbox"/> No <input type="checkbox"/>

Date:

Ward:

Name of person completing this audit form:

QI Methodology

- [UCLP Quality Improvement online course](#)
- [IHI Model for Improvement](#)

What are we trying to accomplish?

How will we know that a change is an improvement?

What change can we make that will result in improvement?



Source: Adapted from The Improvement Guide (2009)

QI Methodology: What are we trying to accomplish?

- Forming the right team
- Identifying stakeholders
- Partnering with patients / carers / public




QI Methodology: What are we trying to accomplish?

- Setting aims

S	pecific	Who, what, where, when
M	easurable	Numeric goals, by how much?
A	ttainable	Within your influence
R	elevant	To stakeholders and organisation
T	imely	By when, give a precise date

- Driver diagrams

- Process mapping



QI Methodology: What are we trying to accomplish?


Example

- **Shared purpose:** Reduce the number of new patients on long-term opioids for chronic pain through improved communication between secondary care and primary care
- **Aim:** 100% of discharge letters list the prescribed opioid, include an indication and a stop/review date for all patients started on a new opioid by April 2024.
- **Team:** Pharmacists and doctors (primary and secondary care), discharge service team, hospital administrators, patients/experts by experience

QI Methodology: What are we trying to accomplish?

Example

- **Drivers:**




- **Process mapping**



QI Methodology: What changes can we make that will result in improvement?

Change ideas

- Something specific enough to test and implement in any given situation. They are an actual change to the current process.
- Properties of a useful change idea:
 - Specific: can you describe what will happen when the data is used? Can you describe who, what, when, where, why, and how the idea will be put into practice?
 - Actionable/Feasible: Can you envision using the idea with current technology, resources and authority?




QI Methodology: How will we know a change is an improvement?




QI Methodology: How will we know a change is an improvement?

Statistical Process Control (SPC) chart

- Average (usually mean), upper and lower limits
- 4 Rules
- [NHSE&I QSIR tools - SPC](#)



QI Methodology: Plan, Do, Study, Act (PDSA) Cycles



QI Methodology: Plan, Do, Study, Act (PDSA) Cycles




QI Methodology: Plan, Do, Study, Act (PDSA) Cycles

Aim: 100% of discharge letters list the prescribed opioid, include an indication and a stop/review date for all patients started on a new opioid by April 2024.

	PLAN	DO	STUDY	ACT
PDSA 1	<p>Would a discharge letter template which includes all the elements relevant to opioids improve completeness?</p> <p>How will you measure change, acceptability?</p>	<p>Co-develop the template with stakeholders</p> <p>Train stakeholders on the reason for change and on completing the template</p>	<p>Run baseline audit, rerun audit to check DL completeness</p> <p>Survey staff to check for ease of use, acceptability</p>	<p>Template works → spread to other hospitals?</p> <p>Template doesn't work → why? Change or scrap?</p>
PDSA 2	<p>Do the stakeholders writing the discharge letters understand the impact of including the elements relevant to opioids?</p> <p>Would they benefit from training?</p>	<p>Co-develop a training session/programme with stakeholders</p> <p>Conduct training</p>	<p>Training attendance</p> <p>Survey staff to measure changes in knowledge, attitude</p> <p>Run baseline audit, rerun audit to check DL completeness</p>	<p>Training works → spread to other hospitals?</p> <p>Training doesn't work → why? Change or scrap?</p>

QI Methodology: Plan, Do, Study, Act (PDSA) Cycles

Aim: 100% of discharge letters list the prescribed opioid, include an indication and a stop/review date for all patients started on a new opioid by April 2024.



Next Steps

- Further reading / training
 - [UCLP Quality Improvement online course](#)
 - [IHI Model for Improvement](#)
 - [Learning and Improving Across Systems Peer Learning Programme](#)
- Run / re-run audit
- Ask questions
- Share results and learning

Thank you

Special thanks to Amandeep Setra and Nikki Glover

For more information please contact:

Jessica Catone

Jessica.catone@uclpartners.com

www.uclpartners.com

@uclpartners